Last reviewed · How we verify
Instillation of IMUNO BCG Moreau RJ
Instillation of IMUNO BCG Moreau RJ is a Biologic drug developed by Biofabri, S.L. It is currently in Phase 2 development.
At a glance
| Generic name | Instillation of IMUNO BCG Moreau RJ |
|---|---|
| Sponsor | Biofabri, S.L |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Instillation of IMUNO BCG Moreau RJ CI brief — competitive landscape report
- Instillation of IMUNO BCG Moreau RJ updates RSS · CI watch RSS
- Biofabri, S.L portfolio CI
Frequently asked questions about Instillation of IMUNO BCG Moreau RJ
What is Instillation of IMUNO BCG Moreau RJ?
Instillation of IMUNO BCG Moreau RJ is a Biologic drug developed by Biofabri, S.L.
Who makes Instillation of IMUNO BCG Moreau RJ?
Instillation of IMUNO BCG Moreau RJ is developed by Biofabri, S.L (see full Biofabri, S.L pipeline at /company/biofabri-s-l).
What development phase is Instillation of IMUNO BCG Moreau RJ in?
Instillation of IMUNO BCG Moreau RJ is in Phase 2.